Tocopheryl nicotinate


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Hyperlipedaemia; Symptoms associated w/ HTN; Symptoms associated w/ cerebral arteriosclerosis and sequelae of cerebral apoplexy; Peripheral circulatory disturbance resulting from arteriosclerosis obliterans 100-200 mg for 3 times/day; may adjust dose based on patient's age and symptoms.
Dosage Details
Oral
Hyperlipidaemias
Adult: 100-200 mg tid, adjust dose based on patient's age and symptoms.

Oral
Symptoms associated with hypertension, Symptoms associated with cerebral arteriosclerosis and sequelae of cerebral apoplexy, Peripheral circulatory disturbance resulting from arteriosclerosis obliterans
Adult: 100-200 mg tid, adjust dose based on patient's age and symptoms.
Adverse Reactions
Nausea, diarrhoea, constipation, stomach ache/discomfort, anorexia, rash, flushing, oedema, and liver dysfunction (elevated AST, ALT).
Food Interaction
Higher absorption when administered after a meal.
Action
Description: Tocopheryl nicotinate is the esterified compound of tocopherol and nicotinic acid which has more potent pharmacological activity than a dose of both drugs given concurrently. Tocopheryl nicotinate is a lipid regulating drug which can reduce total serum cholesterol and triglycerides, and increase HDL cholesterol. It has also been shown to enhance microcirculation, inhibit platelet aggregation, prevent capillary fragility, and restore arterial oxygen partial pressure.
Pharmacokinetics:
Absorption: Following a single oral admin of 600 mg dose, Tmax of Tocopheryl nicotinate (unchanged form): About 6 hr; tocopherol (hydrolysed form): About 10 hr.
Excretion: Elimination half-life of Tocopheryl nicotinate: About 4.3 hr; tocopherol (hydrolysed form): About 38.5 hr.
Storage
Store at room temperature. Protect from heat and moisture.
Disclaimer: This information is independently developed by MIMS based on Tocopheryl nicotinate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in